Prana discontinues PBT1 development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Further development of Prana's investigational Alzheimer's agent clioquinol (PBT1) is "not warranted," the Australian firm says April 11. The firm has decided not to begin the "potentially pivotal" Phase II/III PLACQUE trial after finding that "unacceptably high levels of a di-iodo (toxic) form of PBT1" occur in the synthetic process of the drug. While Prana "has considered methods to reduce the levels of di-iodo impurity, it has come to the conclusion that attempts to reduce the impurity to safe levels are not likely to be successful in a timely manner." A "strategic review" of Prana's R&D programs is underway; a follow-on compound to PBT1 - PBT2 - is in Phase I...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.